PTJ
CNCE

Paul Tudor Jones’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Paul Tudor Jones’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-17,554
Closed -$118K – 2993
2022
Q3 		$118K Sell
17,554
-28,134
-62% -$171K ﹤0.01% 2146
2022
Q2 		$192K Hold
45,688
– – 0.01% 1835
2022
Q1 		$154K Hold
45,688
– – ﹤0.01% 1804
2021
Q4 		$144K Sell
45,688
-34,144
-43% -$114K ﹤0.01% 2210
2021
Q3 		$261K Buy
79,832
+8,917
+13% +$31.2K ﹤0.01% 2139
2021
Q2 		$299K Sell
70,915
-9,277
-12% -$39.3K 0.01% 1346
2021
Q1 		$400K Buy
+80,192
New +$648K 0.01% 1213
2019
Q4 		– Sell
-20,898
Closed -$123K – 1440
2019
Q3 		$123K Buy
20,898
+1,838
+10% +$19.5K ﹤0.01% 989
2019
Q2 		$229K Buy
+19,060
New +$205K 0.01% 931
2018
Q2 		– Sell
-19,290
Closed -$442K – 1282
2018
Q1 		$442K Buy
+19,290
New +$429K 0.01% 610
2016
Q4 		– Sell
-11,507
Closed -$116K – 1666
2016
Q3 		$116K Sell
11,507
-1,075
-9% -$11.7K ﹤0.01% 1325
2016
Q2 		$141K Sell
12,582
-700
-5% -$8.91K ﹤0.01% 1478
2016
Q1 		$181K Buy
+13,282
New +$191K ﹤0.01% 1525
2015
Q2 		– Sell
-51,025
Closed -$773K – 1728
2015
Q1 		$773K Buy
+51,025
New +$712K 0.02% 491

Other funds holding CNCE

KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Paul Tudor Jones's CNCE Position: Q4 2022 in Review

Paul Tudor Jones sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q4 2022, closing a stake of 17,554 shares — an estimated $118K sold.

Paul Tudor Jones first reported a position in CNCE in Q1 2015 and held it in 14 quarters. The position peaked at $773K in Q1 2015. 85 funds tracked by Wall St. Rank hold CNCE as of Q4 2022.

  • Paul Tudor Jones reported no remaining Concert Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
  • Paul Tudor Jones sold 17,554 Concert Pharmaceuticals, Inc. shares in Q4 2022, an estimated $118K.
  • Paul Tudor Jones first reported a position in Concert Pharmaceuticals, Inc. in Q1 2015 and held it in 14 quarters.
  • Paul Tudor Jones's Concert Pharmaceuticals, Inc. position peaked at $773K in Q1 2015.
  • 85 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q4 2022.

Based on Tudor Investment Corp's 13F filing for Q4 2022, filed 14 Feb 2023.